A groundbreaking study from Mass General Brigham has revealed a novel approach to combating glioblastoma, one of the most aggressive and treatment-resistant brain tumors. Researchers have engineered a herpes simplex virus (HSV-1) to stimulate the immune system's attack on glioblastoma cells, resulting in remarkable outcomes. A single dose of the modified virus significantly boosted T-cell, natural killer cell, and myeloid cell responses within the tumor microenvironment, leading to increased overall survival in preclinical models. The findings were published in Nature Cancer, offering a glimmer of hope in the fight against this devastating disease.
Glioblastoma's resistance to immune system attacks has been a significant challenge. The tumor cells release various molecules that suppress immune responses, making it difficult for the body's natural defenses to combat the cancer. To overcome this hurdle, the research team modified the HSV-1 virus to target specific markers found exclusively on glioblastoma cells. They engineered the virus to express five distinct immunomodulatory molecules, including IL-12, anti-PD1, a bispecific T cell engager, 15-hydroxyprostaglandin dehydrogenase, and anti-TREM2, to reprogram the tumor environment. Additionally, they incorporated safety mutations, or 'off-switches', to prevent the virus from spreading to neurons or healthy central nervous system cells, ensuring patient safety.
The results were impressive. Mice treated with the modified virus exhibited increased infiltration of tumor-fighting T cells and reduced T-cell exhaustion markers. Crucially, these mice survived longer than their counterparts with glioblastoma who did not receive the virus. This breakthrough not only highlights the potential of oncolytic viruses in glioblastoma immunotherapy but also opens up new avenues for cancer treatment, as researchers plan to evaluate the safety and efficacy of the oncolytic virus in human trials and adapt the viral platform for other cancers.
As Francisco J. Quintana, PhD, from the Mass General Brigham Department of Neurology and senior author of the study, states, 'We engineered a safe and traceable oncolytic virus with strong cytotoxic and immunostimulatory activities for glioblastoma immunotherapy. This platform offers a multipronged approach - precise tumor targeting, local delivery of immunotherapeutic payloads, and a built-in safety system to protect normal brain cells.' The study's DOI is 10.1038/s43018-025-01070-6, and further research is underway to explore the virus's potential in human trials and its adaptability for other cancer types.
